IgA nephropathy
Conditions
Interventions
Intervention group:Low-dose corticosteroids combined with Nefecon
Sponsors
General Hospital of Ningxia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Primary IgA nephropathy confirmed by renal biopsy; 2. Age>=18 years old; 3. 24h UTP>1.0g; 4. Estimated glomerular filtration rate (eGFR) >30ml/min/1.73m^2; 5. The patient or guardian voluntarily signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary IgA nephropathy; 2. Combined with severe liver impairment (Child-Pugh grade C), congestive heart failure and malignant tumors; 3. Allergy to budesonide or any of the ingredients in budesonide enteric-coated capsules; 4. Budesonide enteric-coated capsule treatment within 12 weeks before treatment, including but not limited to systemic hormonal therapy (prednisone, methylprednisolone, etc.), immunosuppressive therapy: cyclophosphamide, cyclosporine, azathioprine, mycophenolic acid, calcineurin inhibitors, etc., biologics targeting B cells: tetanercept, etc.; Pregnant and lactating females. 5. Uncontrolled diabetes mellitus and glycosylated hemoglobin (HbA1c) >8.5%; 6. Hepatitis B (hepatitis surface antigen positive or core antibody with surface antibody negative) or hepatitis C virus infection (HCV antibody positive); 7. Active systemic bacterial, viral, or fungal infection within 14 days prior to enrollment; 8. Nephrotic syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein-to-creatinine ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Estimated Glomerular Filtration Rate;B cell activating factor;A proliferation inducing ligand;Galactose-deficient IgA1; | — |
Countries
China
Contacts
Public ContactXiaoling Zhou
General Hospital of Ningxia Medical University
Outcome results
None listed